Search

US-20260124261-A1 - STRAIN OF SACCHAROMYCES CEREVISIAE VAR. BOULARDII FOR TREATING INFECTIOUS DISEASES OF THE ORAL CAVITY

US20260124261A1US 20260124261 A1US20260124261 A1US 20260124261A1US-20260124261-A1

Abstract

A yeast strain of Saccharomyces cerevisiae var. Boulardii for the treatment and/or the prevention of infectious diseases of the oral cavity, such as dental caries and periodontal diseases. This strain can be used either alone or in combination with the inactive dry form of a yeast strain of Saccharomyces cerevisiae.

Inventors

  • Nathalie BALLET
  • Amélie DECHERF
  • Elodie DEHAY-HARMEL

Assignees

  • LESAFFRE ET COMPAGNIE

Dates

Publication Date
20260507
Application Date
20260105
Priority Date
20181219

Claims (16)

  1. 1 . A method for treating an infectious disease of the oral cavity in a subject, the method comprising a step of administering to said subject an effective amount of: a combination of a Saccharomyces cerevisiae var. boulardii yeast strain deposited, on Aug. 21, 2007, at the CNCM under number I-3799, with an inactivated dry form of a Saccharomyces cerevisiae yeast strain deposited, on Oct. 17, 2007, at the CNCM under number I-3856, wherein the infectious disease of the oral cavity is dental caries, gingivitis or periodontitis, and wherein the infectious disease of the oral cavity is a side effect of a medical treatment, or wherein the subject is a patient with immune vulnerability, or the subject exhibits reduced salivary flow, or the subject is a pregnant woman.
  2. 2 . The method according to claim 1 , wherein said medical treatment comprises, or consists of, administration of an immunosuppressant, phenytoin, or a calcium channel blocker to said subject.
  3. 3 . The method according to claim 1 , wherein said immune vulnerability is associated with Sjögren's syndrome, HIV infection, uncontrolled diabetes, endocrine disorders, malnutrition or malabsorption.
  4. 4 . The method according to claim 1 , wherein said subject exhibiting reduced salivary flow is an elderly subject or a smoker or a subject under stress.
  5. 5 . The method according to claim 1 , wherein the Saccharomyces cerevisiae var. boulardii yeast is in live dry form.
  6. 6 . The method according to claim 1 , wherein the combination of the Saccharomyces cerevisiae var. boulardii yeast strain with the inactivated dry form of the Saccharomyces cerevisiae yeast strain is comprised in a dietary supplement.
  7. 7 . The method according to claim 6 , wherein the dietary supplement is in the form of a lozenge to be sucked, a candy, a chewing gum, an orodispersible powder or a powder to be diluted in water in the form of a stick or sachet, a tablet to be sucked or chewed, a gum, a capsule, a tablet, drops, or a vial with a measuring cap.
  8. 8 . The method according to claim 1 , wherein the combination of the Saccharomyces cerevisiae var. boulardii yeast strain with the inactivated dry form of the Saccharomyces cerevisiae yeast strain is comprised in a parapharmaceutical or cosmetic composition.
  9. 9 . The method according to claim 8 , wherein the parapharmaceutical or cosmetic composition is in the form of a toothpaste, a mouthwash, an oral spray, an oral cream or gel, an orodispersible sheet, a powder to be sprinkled directly into the oral cavity, an orodispersible powder or a powder to be diluted in water in the form of a stick or sachet, or a vial with a measuring cap.
  10. 10 . The method according to claim 1 , wherein the combination of the Saccharomyces cerevisiae var. boulardii yeast strain with the inactivated dry form of the Saccharomyces cerevisiae yeast strain is comprised in a pharmaceutical composition, which further comprises at least one physiologically acceptable excipient.
  11. 11 . The method according to claim 10 , wherein the pharmaceutical composition is in a form for topical administration or for oral administration.
  12. 12 . The method according to claim 10 , wherein the pharmaceutical composition further comprises at least one additional pharmaceutical active principle having soothing, anti-irritant, analgesic, antalgic, anti-inflammatory, healing, antibiotic, antipyretic, or antifungal activity.
  13. 13 . The method according to claim 1 , wherein the combination of the Saccharomyces cerevisiae var. boulardii yeast strain with the inactivated dry form of the Saccharomyces cerevisiae yeast strain is comprised in a dental medical device.
  14. 14 . The method according to claim 13 , wherein said dental medical device is dental implant, a dental crown, a dental bridge, a dental onlay, or a dental prosthesis.
  15. 15 . The method according to claim 1 , wherein the infectious disease of the oral cavity is caused by periodontopathogenic bacteria and/or cariopathogenic bacteria.
  16. 16 . The method according to claim 15 , wherein the periodontopathogenic bacteria are selected from Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum, Porphyromonas gingivalis, Prevotella intermedia , and/or the cariopathogenic bacterium Streptococcus mutans.

Description

RELATED PATENT APPLICATIONS The present patent application is a divisional of U.S. patent application Ser. No. 17/414,084, filed on Jun. 15, 2021, which is filed pursuant to 35 U.S.C. § 371 as a U.S. National Phase application of International Patent Application No. PCT/EP2019/086265, which was filed on Dec. 19, 2019, claiming the benefit of priority to French patent application number FR 18 73321 filed on Dec. 19, 2018. The content of each of the aforementioned patent applications is incorporated herein by reference in its entirety. FIELD The present invention relates to the field of oral health. More particularly, the invention relates to a Saccharomyces cerevisiae var. boulardii strain, used alone or in combination with an inactivated dry Saccharomyces cerevisiae yeast, in the treatment and/or prevention of infectious diseases of the oral cavity, such as dental caries and periodontal disease. BACKGROUND In man, the oral cavity is an ecosystem which is complex, open to the interior, and inhabited by numerous microorganisms including more than 700 bacterial species detected (Ghannoum et al., PLOS Pathog., 2010; 6: e1000713; Marsh et al., Periodontol., 2000, 55:16-35; Paster et al., Periodontol., 2000, 42:80-87). For a given individual, the number of resident bacterial species varies from 150 to 250. Most of these species are commensal and necessary to maintain the balance of this ecosystem. However, in certain situations (high carbohydrate intake, tobacco use, or physiological changes such as aging, puberty or pregnancy, etc.), a disruption of this balance occurs and can lead to the development of infectious diseases of the oral cavity. The main infectious diseases of the oral cavity are dental caries and periodontal disease. Dental caries are a polybacterial disease that manifests itself by a demineralization of the hard tissues of the tooth. This demineralization is due to the production of acids by the fermentative bacteria present in the dental plaque. Mutans group streptococci and lactobacilli are considered as the main cariogenic bacteria. The World Health Organization (WHO) report on oral health notes the high prevalence of caries, in particular among the youngest. Compared with the rest of the world, the risk of childhood caries is much higher in developed countries (North America, Australia, Europe, Japan), due to a diet very high in sugar in these countries. Periodontal diseases are a group of pathologies affecting the periodontium (i.e., the tissues supporting the tooth-bone and gingival mucosa). These diseases are divided into two main categories: gingivitis and periodontitis. Gingivitis is any inflammation limited to the superficial periodontium. Periodontitis is an advanced infectious lesion of the periodontium and often follows gingivitis. The presence of certain bacteria and an intense inflammatory response lead to the destruction of the periodontium. The change from a healthy state to a state of periodontal disease is accompanied by a progressive transition to a flora richer in anaerobic and Gram-negative bacteria. This phenomenon is called anaerobic drift. The bacterial species most frequently involved in periodontal disease include: Fusobacterium nucleatum and Porphyromonas gingivalis whose co-aggregation seems to improve their survival and pathogenicity (Diaz et al., Microbiology, 2002, 148:467-472; Saito et al., FEMS Immunol. Med. Microbiol., 2008, 54:349-355; Polak et al., J. Clin. Periodontol., 2009, 36:406-410). The treatment of dental caries, which affect only the enamel or dentin, includes a filling with a composite or silver amalgam. When the tooth is severely damaged, the dentist will perform a restoration using a crown; and if the nerve is affected, a root canal must be performed. Untreated caries continue to progress and bacteria eventually attack the alveolar bone under the root, leading to a painful abscess that must be treated with antibiotics and then proceed to mechanical treatment. Antibiotics are also used in the treatment of periodontal disease in combination with scaling and root planing, curettage, dental surgery or as a lone treatment to reduce bacteria before and/or after these common periodontal procedures. The intensive use of antibiotics has introduced a selection pressure leading to the concerning development of populations of antibiotic-resistant microorganisms and to a general decrease in therapeutic efficacy. These resistances, which were initially sporadic, have become massive and worrying. Some bacterial strains have become multiresistant, i.e., resistant to several antibiotics, and other strains have become totally resistant, i.e., resistant to all available antibiotics. Fortunately, the latter case is still rare, but the phenomenon is increasing and puts physicians in a therapeutic impasse. Thus, in the current context of increasing and worrying antibiotic resistance, scientists and health professionals are seeking to identify new therapeutic strategies,